189 results
Page 3 of 10
6-K
EX-99.3
tbxgvzgpvroflewv62sw
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.4
872g8drrgnsjz7wlbhxu
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.1
6s3r0
29 Mar 22
RepliCel Announces Non-brokered Private Placement
1:02pm
6-K
EX-99.1
f3rldl6i3cb9g9ag
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
EX-99.2
5ad1pm75 3260i9zd9
21 Dec 21
51-102F3 Material Change Report
5:28pm
6-K
EX-99.3
1um 6xf0uwb
21 Dec 21
51-102F3 Material Change Report
5:28pm
6-K
EX-99.1
svp0hee
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
1wfofri6tnxzes0r
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
9cf1rsy
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.2
yg3t sqq8afob8wf4kw
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.2
cwf30m2
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.1
07qch 8c7e3kj
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.3
t1vhoe1b6gwm0xi6oju
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.1
xghx36cpttcvaba1l
21 Oct 21
Current report (foreign)
3:49pm
6-K
EX-99.1
h9tzfe lfvzgc
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
rnwpr7 u2f5
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.1
i30dy35g7pkb0ck0
12 Oct 21
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
1:06pm
6-K
EX-99.2
5z1c2j
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
l8m4drojpfmr28g
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
xp2ipa34rt3 hmn9hclr
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm